Buys
Open market- Shares
- Avg price
- Total value
Bernadette Connaughton - Director at HALOZYME THERAPEUTICS, INC.
Issuer-level insider activity
- Role
- Director
- Issuer ticker
- HALO on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Bernadette Connaughton in HALOZYME THERAPEUTICS, INC.
Sells
Open market- Shares
- -17,330
- Avg price
- $74.12
- Total value
- -$1,284,583
Net
Past year- Shares
- -17,330
- Share %
- -100%
- Total value
- -$1,284,583
Reported holdings for Bernadette Connaughton in HALOZYME THERAPEUTICS, INC.
Form 4 holding
Director
HALOZYME THERAPEUTICS, INC.
- Security class
- Common Stock
- Shares / value
- 40,418
- Estimated value
- $4,154,970
- Report date
- 10 Aug 2026
- Price
- $102.80
- Ownership
- Direct
Form 4 holding
Director
HALOZYME THERAPEUTICS, INC.
- Security class
- Option to Purchase Common Stock
- Shares / value
- 6,040
- Estimated value
- Report date
- 05 May 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Bernadette Connaughton in HALOZYME THERAPEUTICS, INC.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.